Wykoff CC, et al. – A TREX–AMD randomised trial was conducted to prospectively assess outcomes in the third year of neovascular age–related macular degeneration (AMD) management utilizing ranibizumab with the continued treatment and extend (TREX) dosing compared with monthly visits with retreatment upon evidence of exudative disease activity (PRN, pro re nata). Upon transition to PRN, subjects randomised to monthly dosing experienced a decline in BCVA. Among subjects initially randomised to TREX who transitioned to PRN after achieving a 12–week interval between visits, the overall need for additional treatment was low.